¼Ò¾Æû¼Ò³â ÀÌ»óÁöÇ÷ÁõÀÇ À¯º´·ü ¹× Ä¡·á
Prevalence and treatment of pediatric dyslipidemia
´ëÇÑÀÇ»çÇùȸÁö 2021³â 64±Ç 6È£ p.410 ~ p.415
¼Û°æö(Song Kyung-Chul) - Yonsei University College of Medicine Department of Pediatrics
±èÈ£¼º(Kim Ho-Seong) - Yonsei University College of Medicine Department of Pediatrics
äÇö¿í(Chae Hyun-Wook) - Yonsei University College of Medicine Department of Pediatrics
Abstract
Background: As dyslipidemia at a young age is a risk factor for cardiovascular disease in adulthood, the screening and management of dyslipidemia in children and adolescents might be an important health issue. This review deals with issues related to the prevalence, diagnosis, screening, and treatment of pediatric dyslipidemia.
Current Concepts: In Korea, the prevalence of pediatric dyslipidemia was 19.7% between 2007 and 2009. Dyslipidemia was defined according to the guidelines of the Korean Society of Pediatric Endocrinology: total cholesterol ¡Ã200 mg/dL, low-density lipoprotein cholesterol ¡Ã130 mg/dL, triglycerides ¡Ã130 mg/dL, high-density lipoprotein cholesterol <40 mg/dL, or non-high-density lipoprotein cholesterol ¡Ã145 mg/dL.
Discussion and Conclusion: We recommend universal screening tests for dyslipidemia at ages 9?11 years and 17?21 years. Diet and lifestyle modifications are essential in the treatment of dyslipidemia. In children aged ¡Ã10 years with a poor response to lifestyle modification, drug therapy is recommended. Pediatric dyslipidemia should be diagnosed and treated properly to reduce adult cardiovascular diseases and improve quality of life in this age group.
Å°¿öµå
ÀÌ»óÁöÇ÷Áõ, À¯º´·ü, Ä¡·á, ¼Ò¾Æ, û¼Ò³â
Dyslipidemia, Prevalence, Treatment, Child, Adolescent
¿ø¹® ¹× ¸µÅ©¾Æ¿ô Á¤º¸
µîÀçÀú³Î Á¤º¸
À¯È¿¼º°á°ú(Recomendation)
This article recommend universal screening tests for dyslipidemia at ages 9-11 years and 17-21 years. Diet and lifestyle modifications are essential in the treatment of dyslipidemia.